Given the rapidly evolving landscape of Artificial Intelligence, one of the biggest hurdles tech leaders often come across is ...
Vertex Pharmaceuticals is scheduled to post its fourth-quarter results soon, and analysts project a double-digit earnings ...
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...
In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...
Zacks Investment Research on MSN
Implied volatility surging for Vertex Pharmaceuticals stock options
Investors in Vertex Pharmaceuticals Incorporated VRTX need to pay close attention to the stock based on moves in the options ...
Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans multiple ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results